Our lab has recently shown that IL-19 is expressed in angiogenic ECs, opening the possibility for its use as a medicine to increase perfusion in patients with PAD. The first aim of the current study is to show IL-19’s ability to increase perfusion in vivo using C57BL/6 wild type and IL-19 KO mice in the hindlimb ischemia (HLI) model. Wild-type mice injected with 10ng/g/day of rmIL-19 after being subject to hindlimb ischemia showed significantly greater...